<DOC>
	<DOCNO>NCT02373449</DOCNO>
	<brief_summary>Neuropathic nerve injury relate pain ( NP ) , extremely unpleasant condition difficult treat , often severe , persistent , unremitting course . Conventional treatment often ineffective relieve NP . Recently , investigator develop cost-efficient regimen involve use low dose infusion ketamine treat neuropathic pain patient oral medication fail . We observe excellent benefit many patient . However , treatment require titration monitor infusion currently possible predict patient benefit intervention . The investigator show functional magnetic resonance imaging ( fMRI ) brain use tool predict relief pain assess effect treatment chronic pain condition . This innovative project involve development fMRI-guided treatment intravenous ketamine patient NP . This study aim analyze pattern change fMRI brain , infusion ketamine correlate change pain intensity . The information study help deliver therapy earlier patient likely benefit ketamine .</brief_summary>
	<brief_title>Ketamine fMRI Neuropathic Pain</brief_title>
	<detailed_description>This trial exploratory , prospective , non-randomized , single cohort , single-center , blind participant , treat physician , investigator . Study participant undergo resting-state fMRI , ' 1-month post-ketamine infusion ' ( standard care ) . Patients recruit 2 year , Pain Clinics Toronto Western Hospital Mount Sinai Hospital . The primary null hypothesis trial fMRI brain pattern patient neuropathic pain predict pain relief follow ketamine infusion . The secondary null hypothesis trial correlation specific fMRI brain pattern patient neuropathic pain change intensity pain immediately follow ketamine infusion . Further secondary hypothesis include cortical reorganization brain measure fMRI one month infusion ketamine correlate persist analgesic benefit patient neuropathic pain . Finally , hypothesize ketamine infusion provide significant pain relief , reduction anxiety depression , improvement quality life early ( 1 month ) late ( 3 month ) infusion patient neuropathic pain .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>Refractory neuropathic pain diagnose &gt; 3 score DN4 ( Douleur Neuropathique 4 ) questionnaire Average daily pain intensity moderate severe , indicate &gt; 3 score NRS ( Numerical Rating Scale ) Duration neuropathic pain three month Participants try least three medication neuropathic pain . Each medication belong different pharmacological group : anticonvulsant ( gabapentin , pregabalin ) , tricyclic antidepressant ( amitriptyline , nortriptyline , imipramine , desipramine ) , serotonin noradrenaline reuptake inhibitor ( venlafaxine , duloxetine ) , tramadol , opioids , cannabinoids , methadone , topical lidocaine capsaicin patch . Ketamine lidocaine intravenous infusion within 6 month precede enrollment trial Contraindications ketamine ( allergy , pregnancy , uncontrolled arterial hypertension , uncontrolled hyperthyroidism , severe ischemic heart disease heart failure , severe liver kidney disease , space occupy lesion brain spinal cord , uncontrolled epilepsy glaucoma ) Ongoing litigation issue relate patient 's pain may affect report pain quality life An unstable medical psychiatric condition make unsafe use study medication Participants unable comply study protocol ( e.g . followup visit , fill form measure anxiety , depression , quality life ) Relative ( claustrophobia ) absolute contraindication MRI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Ketamine</keyword>
	<keyword>fMRI</keyword>
	<keyword>refractory neuropathic pain</keyword>
</DOC>